secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001104659-22-036114
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M
--------------------------------------------------------------------------------

- Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).
- Q4 net loss $8.6M vs $7.8M; FY net loss $33.3M vs $28.8M.
- Gross margin improved to 68% in Q4; full-year 64%.
- Cash $43.9M at Dec 31, 2021.
- FY2022 revenue guidance $40-$45M; preliminary Q1 2022 revenue ~$8.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922036114/0001104659-22-036114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922036114/tm229728d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-036114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer